These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 7578657

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
    de Leeuw AS, Westenberg HG.
    J Psychiatr Res; 2008 Sep; 42(11):894-901. PubMed ID: 18533183
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile.
    Feuchtl A, Bagli M, Stephan R, Frahnert C, Kölsch H, Kühn KU, Rao ML.
    Pharmacopsychiatry; 2004 Jul; 37(4):180-8. PubMed ID: 15467976
    [Abstract] [Full Text] [Related]

  • 5. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
    Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J.
    Neuropsychobiology; 2004 Jul; 50(3):200-5. PubMed ID: 15365215
    [Abstract] [Full Text] [Related]

  • 6. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
    Khanna S, John JP, Reddy LP.
    Psychoneuroendocrinology; 2001 Feb; 26(2):209-23. PubMed ID: 11087965
    [Abstract] [Full Text] [Related]

  • 7. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.
    Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, Murphy DL.
    Biol Psychiatry; 1993 Jan 01; 33(1):3-14. PubMed ID: 8420593
    [Abstract] [Full Text] [Related]

  • 8. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
    Hollander E, DeCaria C, Gully R, Nitescu A, Suckow RF, Gorman JM, Klein DF, Liebowitz MR.
    Psychiatry Res; 1991 Jan 01; 36(1):1-17. PubMed ID: 2017519
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH.
    J Clin Psychopharmacol; 1993 Oct 01; 13(5):354-8. PubMed ID: 8227493
    [Abstract] [Full Text] [Related]

  • 12. [Validation of a scale for responsibility (Salkovskis Responsibility Scale)].
    Bouvard M, Robbe-Grillet P, Milliery M, Pham S, Amireche S, Fanget F, Guerin J, Cottraux J.
    Encephale; 2001 Oct 01; 27(3):229-37. PubMed ID: 11488253
    [Abstract] [Full Text] [Related]

  • 13. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor.
    Stein DJ, Van Heerden B, Wessels CJ, Van Kradenburg J, Warwick J, Wasserman HJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Aug 01; 23(6):1079-99. PubMed ID: 10621951
    [Abstract] [Full Text] [Related]

  • 14. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
    Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR.
    Arch Gen Psychiatry; 1988 Feb 01; 45(2):177-85. PubMed ID: 3337615
    [Abstract] [Full Text] [Related]

  • 15. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder.
    Katzman MA, Koszycki D, Bradwejn J.
    Depress Anxiety; 2004 Feb 01; 20(2):51-8. PubMed ID: 15390214
    [Abstract] [Full Text] [Related]

  • 16. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology.
    Korff S, Harvey BH.
    Psychiatr Clin North Am; 2006 Jun 01; 29(2):371-90. PubMed ID: 16650714
    [Abstract] [Full Text] [Related]

  • 17. Empathy and symptoms dimensions of patients with obsessive-compulsive disorder.
    Fontenelle LF, Soares ID, Miele F, Borges MC, Prazeres AM, Rangé BP, Moll J.
    J Psychiatr Res; 2009 Jan 01; 43(4):455-63. PubMed ID: 18614180
    [Abstract] [Full Text] [Related]

  • 18. Neurobiology of obsessive compulsive disorder: a possible role for serotonin.
    Winslow JT, Insel TR.
    J Clin Psychiatry; 1990 Aug 01; 51 Suppl():27-31; discussion 55-8. PubMed ID: 2199432
    [Abstract] [Full Text] [Related]

  • 19. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
    Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL.
    Arch Gen Psychiatry; 1987 Nov 01; 44(11):946-51. PubMed ID: 3675134
    [Abstract] [Full Text] [Related]

  • 20. The distinctiveness of compulsive hoarding from obsessive-compulsive disorder.
    Grisham JR, Brown TA, Liverant GI, Campbell-Sills L.
    J Anxiety Disord; 2005 Nov 01; 19(7):767-79. PubMed ID: 16076423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.